ATEC:NSD-Alphatec Holdings, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 10.95

Change

+0.38 (+3.60)%

Market Cap

USD 0.83B

Volume

2.14M

Average Target Price

USD 11.17 (+1.98%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to meet the surgeon's needs and to maximize patient outcomes; LLICO access system, a minimally invasive posterior thoracolumbar access system; Invictus Spinal Fixation System, a comprehensive thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep designed to improve surgical efficiency without compromising accuracy. It also provides Arsenal spinal fixation system intended for posterior, non-cervical fixation in skeletally mature patients for treating degenerative disc disease, spondylolisthesis, fracture or dislocation, spinal stenosis, curvatures, tumor, pseud arthrosis, and failed previous fusion; zodiac degenerative spinal fixation system, a comprehensive spinal system used to address degenerative spinal conditions and deformity correction; OsseoScrew system to restore the integrity of the spinal column; trestle luxe anterior cervical plate system; and solanas posterior cervico/thoracic fixation system and avalon occipital plate. In addition, the company offers IdentiTi Porous Ti and Transcend Lateral Interbody Implants; Battalion PC; Novel SD; Solus Anterior Lumbar Interbody Fusion System. Further, it is developing EOS imaging products. Additionally, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-1.41 (-0.30%)

USD37.46B 20.31 83.41
PODD Insulet Corporation

-4.75 (-1.87%)

USD16.72B 600.55 148.92
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed, Inc

-1.85 (-0.70%)

USD12.01B 58.95 47.06
BRKR Bruker Corporation

+0.18 (+0.36%)

USD7.70B 50.53 25.11
TNDM Tandem Diabetes Care, Inc

+2.48 (+2.80%)

USD5.52B N/A N/A
IART Integra LifeSciences Holdings ..

-1.33 (-2.39%)

USD4.70B 82.62 21.88
SDC SmileDirectClub, Inc

+0.07 (+0.58%)

USD4.64B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
SWAV ShockWave Medical, Inc

-1.65 (-1.67%)

USD3.38B N/A N/A

ETFs Containing ATEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 54.23% 75% C 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.23% 75% C 82% B-
Trailing 12 Months  
Capital Gain 51.45% 81% B- 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.45% 81% B- 79% C+
Trailing 5 Years  
Capital Gain 280.05% 92% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 280.05% 92% A- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 32.32% N/A N/A 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.32% N/A N/A 86% B
Risk Return Profile  
Volatility (Standard Deviation) 84.19% N/A N/A 11% F
Risk Adjusted Return 38.38% N/A N/A 61% D-
Market Capitalization 0.83B 75% C 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 105.20 1% F 1% F
Price / Cash Flow Ratio -25.03 85% B 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -122.63% 23% F 9% F
Return on Invested Capital -58.53% 32% F 17% F
Return on Assets -15.89% 43% F 22% F
Debt to Equity Ratio 122.50% 17% F 17% F
Technical Ratios  
Short Ratio 1.55 75% C 71% C-
Short Percent 5.18% 39% F 38% F
Beta 1.39 38% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector